Cargando…
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
Autores principales: | Lipson, David A., Han, MeiLan K., Wise, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017567/ https://www.ncbi.nlm.nih.gov/pubmed/33444516 http://dx.doi.org/10.1164/rccm.202012-4494LE |
Ejemplares similares
-
Reply to López-Campos et al. and to Rogliani and Calzetta
por: Martinez, Fernando J., et al.
Publicado: (2021) -
Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021) -
Reply to Thomson, to Neder et al., and to Wouters
por: Han, MeiLan K., et al.
Publicado: (2021) -
Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
por: López-Campos, José Luis, et al.
Publicado: (2021) -
Reply by McCormack et al. to Townsend and Cowl, and to Miller et al.
por: McCormack, Meredith, et al.
Publicado: (2022)